Technical Analysis for RPHM - Reneo Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 1.75 | 5.42% | 0.09 |
RPHM closed up 5.42 percent on Friday, May 17, 2024, on 70 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Jun 5
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| MACD Bearish Centerline Cross | Bearish | 9.38% | |
| Calm After Storm | Range Contraction | 9.38% | |
| Inside Day | Range Contraction | 9.38% | |
| Gapped Down | Weakness | 9.38% | |
| Volume Surge | Other | 8.02% | |
| Wide Range Bar | Range Expansion | 8.02% | |
| Lower Bollinger Band Walk | Weakness | 8.02% |
| Alert | Time |
|---|---|
| Up 5% | 1 day ago |
| Up 1 ATR | 1 day ago |
| Rose Above 20 DMA | 1 day ago |
| Rose Above 10 DMA | 1 day ago |
| Up 3% | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/05/2024
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Research Clinical Trial Stage Pharmaceutical Transcription Factors Carboxylic Acids Intracellular Receptors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Research Clinical Trial Stage Pharmaceutical Transcription Factors Carboxylic Acids Intracellular Receptors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.45 |
| 52 Week Low | 0.9801 |
| Average Volume | 293,884 |
| 200-Day Moving Average | 4.14 |
| 50-Day Moving Average | 1.69 |
| 20-Day Moving Average | 1.70 |
| 10-Day Moving Average | 1.72 |
| Average True Range | 0.10 |
| RSI (14) | 54.13 |
| ADX | 29.22 |
| +DI | 21.83 |
| -DI | 26.45 |
| Chandelier Exit (Long, 3 ATRs) | 1.59 |
| Chandelier Exit (Short, 3 ATRs) | 1.72 |
| Upper Bollinger Bands | 1.84 |
| Lower Bollinger Band | 1.56 |
| Percent B (%b) | 0.66 |
| BandWidth | 16.46 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0066 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.98 | ||||
| Resistance 3 (R3) | 1.95 | 1.86 | 1.94 | ||
| Resistance 2 (R2) | 1.86 | 1.80 | 1.87 | 1.92 | |
| Resistance 1 (R1) | 1.80 | 1.76 | 1.83 | 1.83 | 1.91 |
| Pivot Point | 1.71 | 1.71 | 1.72 | 1.72 | 1.71 |
| Support 1 (S1) | 1.65 | 1.65 | 1.68 | 1.68 | 1.59 |
| Support 2 (S2) | 1.56 | 1.61 | 1.57 | 1.58 | |
| Support 3 (S3) | 1.50 | 1.56 | 1.56 | ||
| Support 4 (S4) | 1.53 |
